PDF(Pubmed)
Abstract：
Autophagy and mitophagy pose unresolved challenges in understanding the pathology of diabetic heart condition (DHC), which encompasses a complex range of cardiovascular issues linked to diabetes and associated cardiomyopathies. Despite significant progress in reducing mortality rates from cardiovascular diseases (CVDs), heart failure remains a major cause of increased morbidity among diabetic patients. These cellular processes are essential for maintaining cellular balance and removing damaged or dysfunctional components, and their involvement in the development of diabetic heart disease makes them attractive targets for diagnosis and treatment. While a variety of conventional diagnostic and therapeutic strategies are available, DHC continues to present a significant challenge. Point-of-care diagnostics, supported by nanobiosensing techniques, offer a promising alternative for these complex scenarios. Although conventional medications have been widely used in DHC patients, they raise several concerns regarding various physiological aspects. Modern medicine places great emphasis on the application of nanotechnology to target autophagy and mitophagy in DHC, offering a promising approach to deliver drugs beyond the limitations of traditional therapies. This article aims to explore the potential connections between autophagy, mitophagy and DHC, while also discussing the promise of nanotechnology-based theranostic interventions that specifically target these molecular pathways.
摘要：
自噬和线粒体自噬在理解糖尿病心脏病（DHC）的病理学方面提出了尚未解决的挑战，其中包括与糖尿病和相关心肌病相关的一系列复杂的心血管问题。尽管在降低心血管疾病（CVD）死亡率方面取得了重大进展，心力衰竭仍然是糖尿病患者发病率增加的主要原因.这些细胞过程对于维持细胞平衡和去除受损或功能失调的组件至关重要。它们参与糖尿病性心脏病的发展使它们成为诊断和治疗的有吸引力的目标。虽然有多种常规诊断和治疗策略可用，DHC继续提出重大挑战。即时诊断,在纳米生物传感技术的支持下，为这些复杂的场景提供了一个有希望的替代方案。尽管常规药物已广泛用于DHC患者，他们对各种生理方面提出了一些担忧。现代医学非常重视纳米技术在DHC中靶向自噬和线粒体自噬的应用，提供了一种有希望的方法来提供超越传统疗法限制的药物。本文旨在探讨自噬之间的潜在联系，线粒体自噬和DHC，同时还讨论了基于纳米技术的专门针对这些分子途径的theranostic干预措施的前景。
